Last edition
News about "Tolebrutinib "
EU Approves Sanofi's Cenrifki (Tolebrutinib) for Multiple Sclerosis
The European Commission (EC) has approved Sanofi’s Cenrifki (tolebrutinib) as the first disability-targeting treatment for adults with Secondary Progressive Multiple Sclerosis (SPMS) without relapses.
Tolebrutinib | 25/06/2026 | By News Bureau | 110
Tiziana Submits Annual Safety Report for Intranasal Foralumab to FDA
Tiziana has submitted its annual safety report for intranasal foralumab to the US FDA, reporting an excellent safety profile based on 37.4 cumulative patient-years of exposure and highlighting the continued need for safer therapies following the FDA’s denial of Sanofi’s tolebrutinib for non-relapsing secondary progressive multiple sclerosis.
Tolebrutinib | 30/12/2025 | By News Bureau | 215
Sanofi to Acquire Dynavax, Expanding Vaccine Portfolio
Sanofi has agreed to acquire Dynavax, strengthening its adult immunisation portfolio with an approved hepatitis B vaccine and a shingles vaccine candidate in phase I/II development. The deal combines Dynavax’s vaccine assets with Sanofi’s global development and commercial capabilities.
Tolebrutinib | 24/12/2025 | By News Bureau | 168
Sanofi Reveals Positive Results of Tolebrutinib in HERCULES Phase 3 Study
In the HERCULES study, nrSPMS was defined at baseline as having an SPMS diagnosis with an expanded disability status scale (EDSS) score between 3.0 and 6.5, no clinical relapses for the previous 24 months and documented evidence of disability accumulation in the previous 12 months.
Tolebrutinib | 03/09/2024 | By Aishwarya | 696
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy